IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
Aggregated presentation by day and by market
| Purchases of own shares from June 17th to 21th 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 6 600 | 120,3723 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 2 400 | 120,4326 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 515 | 120,4006 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 485 | 120,4344 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/06/2024 | FR0010259150 | 7 537 | 119,3154 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/06/2024 | FR0010259150 | 2 463 | 119,0330 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/06/2024 | FR0010259150 | 4 000 | 117,7254 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 5 743 | 117,1677 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 1 957 | 117,1431 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 100 | 117,0000 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 200 | 116,9350 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/06/2024 | FR0010259150 | 2 737 | 115,3567 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/06/2024 | FR0010259150 | 1 263 | 115,0259 | CEUX |
| TOTAL | 36 000 | 118,4864 | ||||
Attachment
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2025 12 31
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025